Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, three-way crossover, Phase 1 trial to quantitatively assess any effects of IV difelikefalin (CR845) on respiratory drive after bolus infusion in healthy volunteers

Trial Profile

A randomized, double-blind, placebo-controlled, three-way crossover, Phase 1 trial to quantitatively assess any effects of IV difelikefalin (CR845) on respiratory drive after bolus infusion in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pain; Pruritus
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Mar 2018 According to a Cara Therapeutics media release, the company presented clinical data on the respiratory effects of I.V. CR845 from this trial at ANESTHESIOLOGY 2017, the American Society of Anesthesiologists annual meeting (in Oct 2017).
    • 24 Apr 2017 Data will be presented as part of the Journal Anesthesiology Symposium at the American Society of Anesthesiology (ASA) Annual Meeting, as reported in a Cara Therapeutics media release.
    • 24 Apr 2017 Summary results published in the Cara Therapeutics Media Release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top